KELOWNA, BC / ACCESSWIRE / January 4, 2024 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to announ.
Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Psilocybin found to reduce chronic pain in rats medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Canadian psychedelics biotech Tryp Therapeutics Inc. has entered into an agreement with Australian publicly-trading drug vehicle developer Exopharm Ltd. for the acquisition of 100% of Tryp’s issued and outstanding common shares.